Background: Here we present the first prospective, large-scale, patient- and rater-blind, randomized controlled trial evaluating the utility of combinatorial pharmacogenomic (PGx) testing...
Background: Pharmacogenomic (PGx) testing is a potential tool to inform clinicians’ treatment decisions for patients with Major Depressive Disorder (MDD). However, there is mixed evidence...
Objectives: The GUIDED trial demonstrated that combinatorial pharmacogenomic (PGx) testing significantly improved the rate of response (p=0.007) and remission (p=0.005) and approached sig...